See more : Kyongbo Pharmaceutical Co., Ltd (214390.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shandong Buchang Pharmaceuticals Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Pfizer Inc. (PFE.NE) Income Statement Analysis – Financial Results
- Lee & Man Chemical Company Limited (0746.HK) Income Statement Analysis – Financial Results
- Dkk-Toa Corporation (6848.T) Income Statement Analysis – Financial Results
- NISSHIN GROUP HOLDINGS Company, Limited (8881.T) Income Statement Analysis – Financial Results
- Adevinta ASA (ADEVY) Income Statement Analysis – Financial Results
Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.buchang.com
About Shandong Buchang Pharmaceuticals Co., Ltd.
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. was a former subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.25B | 14.95B | 15.76B | 16.01B | 14.26B | 13.66B | 13.86B | 12.32B | 11.66B | 10.33B | 8.59B | 7.04B | 5.87B |
| Cost of Revenue | 4.32B | 4.23B | 4.13B | 3.74B | 2.39B | 2.35B | 2.45B | 2.07B | 2.01B | 2.02B | 1.61B | 1.33B | 1.75B |
| Gross Profit | 8.92B | 10.72B | 11.63B | 12.27B | 11.87B | 11.31B | 11.42B | 10.25B | 9.65B | 8.31B | 6.98B | 5.71B | 4.12B |
| Gross Profit Ratio | 67.38% | 71.69% | 73.78% | 76.63% | 83.24% | 82.79% | 82.35% | 83.17% | 82.79% | 80.42% | 81.28% | 81.11% | 70.22% |
| Research & Development | 476.51M | 284.12M | 408.60M | 533.42M | 505.36M | 480.24M | 489.37M | 397.59M | 278.93M | 232.47M | 165.76M | 0.00 | 0.00 |
| General & Administrative | 370.74M | 241.69M | 259.80M | 289.09M | 346.61M | 242.25M | 210.34M | 243.20M | 179.34M | 118.08M | 100.60M | 316.49M | 175.99M |
| Selling & Marketing | 6.11B | 7.48B | 8.30B | 8.37B | 8.08B | 8.04B | 8.29B | 6.85B | 6.57B | 5.97B | 4.98B | 3.76B | 2.45B |
| SG&A | 7.37B | 7.73B | 8.56B | 8.66B | 8.43B | 8.28B | 8.50B | 7.09B | 6.75B | 6.09B | 5.08B | 4.07B | 2.62B |
| Other Expenses | 639.08M | 795.83M | 695.67M | 603.86M | 475.61M | -15.74M | 202.25M | 132.56M | 162.22M | 251.87M | 175.10M | 250.59M | 270.80M |
| Operating Expenses | 8.49B | 8.81B | 9.66B | 9.80B | 9.41B | 9.00B | 9.62B | 8.09B | 7.51B | 6.65B | 5.52B | 4.20B | 2.71B |
| Cost & Expenses | 12.81B | 13.04B | 13.80B | 13.54B | 11.80B | 11.35B | 12.07B | 10.16B | 9.51B | 8.68B | 7.13B | 5.53B | 4.46B |
| Interest Income | 18.19M | 19.87M | 23.73M | 17.28M | 19.12M | 21.20M | 30.31M | 15.99M | 21.96M | 24.92M | 28.80M | 17.04M | -0.29 |
| Interest Expense | 109.93M | 135.10M | 167.29M | 145.05M | 136.78M | 91.62M | 76.76M | 156.76M | 135.84M | 93.77M | 31.03M | 0.00 | 13.19M |
| Depreciation & Amortization | 592.57M | 505.63M | 512.05M | 426.58M | 389.15M | 376.16M | 299.62M | 288.31M | 197.27M | 99.55M | 83.66M | 31.43M | 29.97M |
| EBITDA | 1.10B | -610.53M | 2.26B | 2.92B | 2.88B | 2.65B | 2.26B | 2.56B | 4.16B | 1.96B | 1.70B | 1.51B | 1.42B |
| EBITDA Ratio | 8.28% | 16.22% | 15.77% | 18.29% | 20.40% | 20.20% | 17.32% | 21.85% | 36.47% | 19.63% | 20.19% | 21.75% | 24.24% |
| Operating Income | 436.02M | 1.93B | 1.75B | 2.37B | 2.43B | 2.27B | 1.76B | 1.97B | 3.74B | 1.56B | 1.43B | 1.50B | 1.39B |
| Operating Income Ratio | 3.29% | 12.89% | 11.09% | 14.78% | 17.04% | 16.61% | 12.68% | 16.01% | 32.12% | 15.08% | 16.69% | 21.31% | 23.73% |
| Total Other Income/Expenses | -41.46M | -3.19B | -46.61M | -4.67M | -14.24M | -15.74M | 202.25M | 132.34M | 160.43M | 251.74M | 173.56M | 242.92M | 268.84M |
| Income Before Tax | 394.56M | -1.39B | 1.71B | 2.36B | 2.41B | 2.25B | 1.96B | 2.10B | 3.90B | 1.81B | 1.61B | 1.74B | 1.66B |
| Income Before Tax Ratio | 2.98% | -9.27% | 10.87% | 14.75% | 16.94% | 16.50% | 14.14% | 17.08% | 33.50% | 17.51% | 18.71% | 24.76% | 28.31% |
| Income Tax Expense | 242.69M | 331.59M | 478.29M | 517.55M | 451.48M | 347.11M | 321.38M | 334.70M | 370.36M | 300.95M | 259.61M | 283.59M | 273.85M |
| Net Income | 318.97M | -1.72B | 1.16B | 1.86B | 1.95B | 1.89B | 1.64B | 1.77B | 3.54B | 1.32B | 1.17B | 1.25B | 1.23B |
| Net Income Ratio | 2.41% | -11.49% | 7.37% | 11.63% | 13.65% | 13.82% | 11.81% | 14.36% | 30.34% | 12.81% | 13.60% | 17.78% | 20.92% |
| EPS | 0.29 | -1.55 | 1.17 | 1.68 | 1.74 | 1.65 | 1.42 | 1.69 | 3.42 | 1.28 | 1.13 | 1.21 | 83.67 |
| EPS Diluted | 0.29 | -1.55 | 1.17 | 1.68 | 1.74 | 1.65 | 1.42 | 1.69 | 3.42 | 1.28 | 1.13 | 1.21 | 83.67 |
| Weighted Avg Shares Out | 1.11B | 1.11B | 1.11B | 1.11B | 1.12B | 1.14B | 1.15B | 1.04B | 1.03B | 1.03B | 1.03B | 1.04B | 1.14B |
| Weighted Avg Shares Out (Dil) | 1.11B | 1.11B | 1.11B | 1.11B | 1.12B | 1.14B | 1.15B | 1.04B | 1.03B | 1.03B | 1.03B | 1.04B | 1.14B |
Source: https://incomestatements.info
Category: Stock Reports